

# **Curriculum Vitae (C.V.)**



Last update: 10/18/2024

## **Personal Information**

**First Name:** Ali

**Last Name:** Darvishi

**Date of Birth:** 1991

**Marital Status:** Married

**Military Service Status:** Completed (*Substitute Service Program, National Elites Foundation*)

**Academic Rank:** Assistant Professor

**Highest Degree:** Ph.D. in Health Economics

**Affiliation:** School of Public Health and Safety, Shahid Beheshti University of Medical Sciences

**Phone Number:** +98-9169666301

**Email:** [alidarvishieco@gmail.com](mailto:alidarvishieco@gmail.com)

## Academic Background

**Ph.D. in Health Economics**, Tehran University of Medical Sciences (2017-2022)

*Dissertation Title:* "Designing a Multi-Criteria Decision-Making Model Based on Societal Preferences for Prioritizing Medical Interventions in the Allocation of Public Funds"

*Supervisor:* Dr. Ali Akbari Sari

*Outcome-Focused Dissertation* (Presented and approved at the Secretariat of the Supreme Council of Health Insurance)

**Master's in Health Economics**, Kerman University of Medical Sciences (2014-2016)

*Thesis Title:* "Cost-Benefit Analysis of Infertility Treatments based on the Willingness-to-Pay Approach in Iran"

*Supervisor:* Dr. Reza Goodarzi

**Bachelor's in Economic Sciences – Economics**, Ayatollah Boroujerdi University (formerly Allameh Tabataba'i University Campus) (2010-2014)

## Awards and Honors

- ❖ Ranked 1st nationwide in the entrance exam for the Ph.D. program in Health Economics, Ministry of Health, 2017.
- ❖ Graduated as the top student in the Master's program in Health Economics at Kerman University of Medical Sciences, academic year 2014-2015.
- ❖ Recognized as an outstanding research student by the Vice-Chancellor for Research and Technology, Ministry of Health, for the academic year 2021-2022.
- ❖ Selected for benefits from the National Elites Foundation in 2020 and 2021.
- ❖ Awarded Best Graduate Student in Health Economics at Kerman University of Medical Sciences, 2015.
- ❖ Member of the Center for Talented Students at Tehran University of Medical Sciences.
- ❖ Member of the Center for Talented Students at Kerman University of Medical Sciences.

## Teaching Activities

### ❖ University Courses:

1. **Health Technology Assessment**, Master's in Health Economics, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences - Academic Year 2024-2025
2. **Fundamentals of Health Economics**, Master's in Health Economics, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences - Academic Year 2024-2025
3. **Health Economics**, Bachelor's in Public Health, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences - Academic Years 2023-2024 and 2024-2025
4. **Health Technology Assessment**, Master's in Health Economics, School of Medical Education and E-Learning, Shahid Beheshti University of Medical Sciences - Academic Year 2023-2024
5. **Health Economics**, Master's and Ph.D. in Health Governance, School of Governance, University of Tehran - First Semester of Academic Year 2023-2024
6. **Epidemiology 3/Clinical Trials**, Ph.D. in Nutrition (International), School of Nutrition and Dietetics, Tehran University of Medical Sciences - Academic Year 2022-2023
7. **Health Technology Assessment**, Master's in Health Economics, Tehran University of Medical Sciences - Academic Year 2018-2019
8. **Health Economics and Economic Evaluation**, MPH Program, Tehran University of Medical Sciences - 2018, 2019, and 2022
9. **Advanced Health Economics**, Master's in Health Economics, Tehran University of Medical Sciences - Academic Year 2018-2019
10. **Microeconomics and Macroeconomics**, Associate Degree in Accounting, University of Applied Sciences - Academic Year 2016-2017
11. **Service and Commercial Accounting**, Bachelor's in Accounting, University of Applied Sciences, First Semester of Academic Year 2016

### ❖ **Workshops and Lectures:**

1. **Instructor** at the two-day workshop "Economic Evaluation of Health Interventions," Summer School, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, August 2024
2. **Speaker** at the specialized session on "Introduction of a Practical Model for Prioritizing Funding for Special and Complex Disease Insurance Interventions," National Health Insurance Research Center, Health Insurance Organization of Iran, July 2024
3. **Instructor and Speaker**, seven-day workshop on Advanced Health Technology Assessment, National Institute for Health Research, December 2021 and January 2022
4. **Scientific and Executive Expert**, seven-day workshop on Advanced Health Technology Assessment, National Institute for Health Research, December 2021 and January 2022
5. **Instructor** at the workshop "Methodology for Calculating Equity Indicators in Health Financing," School of Public Health, Tehran University of Medical Sciences, February 2023
6. **Organizer and Instructor** of the workshop on Economic Modeling in Health using TreeAg Software, Tehran University of Medical Sciences – 2018

### Theses Under Supervision or Consultation

- **Pharm.D. Thesis**, School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran Medical Sciences Branch (Ongoing)  
*Title:* "Examining the Financial Burden of Diabetes Management and Treatment Drugs in Iran from 2014 to 2023"  
*Role:* Advisor Professor
- **Pharm.D. Thesis**, School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran Medical Sciences Branch (2023)  
*Title:* "Implementation and Economic Evaluation of an Electronic Drug Integration System at Nikan Hospital"  
*Role:* Advisor Professor
- **Pharm.D. Thesis**, School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran Medical Sciences Branch (2023)  
*Title:* "Economic Evaluation of Glargine and Detemir Insulin Compared to Isophane Insulin in Type 2 Diabetic Patients in Iran"  
*Role:* Advisor Professor

### Approved Research Projects (Ordered by Completion Year)

	<u>Project Title</u>	<u>Institution/Organization</u>	<u>Completion Year</u>	<u>Role</u>
1	Analysis of Cost-Benefit of Infertility Treatments Using Willingness to Pay (WTP) Approach	<i>National Institute for Health Research, Iran</i>	2016	Principal Investigator
2	Evaluation of the Performance of Provincial Units of Social Security Organization in Indirect Treatment from 2012 to 2016	<i>Health Service Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences</i>	2016	Co-Investigator
3	Examining Socioeconomic Aspects of Assisted Reproductive Technologies (ART) in Kerman	<i>Research Department, Kerman University of Medical Sciences</i>	2016	Principal Investigator
4	Assessing Efficiency and Productivity of Medical Universities in Iran Using Data Envelopment Analysis and Malmquist Index	<i>Health Service Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences</i>	2017	Co-Investigator
5	Evaluation of the Financial Burden of Ethical Risks in Pharmaceuticals on Health Insurance	<i>Health Insurance Future Studies Department, Iran Health Insurance Organization</i>	2017	Principal Investigator
6	Analysis of the Household Expenditure Patterns of Iranian Families with Emphasis on Health Expenditures from 2013 to 2016	<i>Health Service Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences</i>	2017	Co-Investigator
7	Estimating the Poverty Line and Poverty Levels as Socioeconomic Factors Affecting Health in Urban and Rural Households in Iran from 2008 to 2016	<i>Health Service Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences</i>	2017	Principal Investigator
8	Evaluation of Safety, Efficacy, and Cost-Effectiveness of Panitumumab vs. Cetuximab in Treating Metastatic Colorectal Cancer	<i>Behestan Darou Company / Food and Drug Administration</i>	2017	Co-Investigator
9	Cost-Effectiveness Analysis of Screening for Gestational Diabetes Using One-Stage and Two-Stage Approaches in Iran	<i>Health Deputy, Ministry of Health</i>	2018	Co-Investigator
10	Evaluation of Safety, Efficacy, and Overview of Cost-Effectiveness of Oral Deferasirox vs. Injectable Deferoxamine in Treating Thalassemia	<i>Treatment Deputy, Ministry of Health - Health Technology Assessment Office</i>	2018	Co-Investigator
11	Performance Evaluation and Measurement of Educational	<i>Health Service Management Research Center, Institute for Futures Studies in Health,</i>	2018	Co-Investigator

	Productivity of Medical Universities in Iran Using Data Envelopment Analysis and Malmquist Index	<i>Kerman University of Medical Sciences</i>		
12	Examining the Rate of Encounter with Catastrophic Health Expenditures and the Distribution Inequality Before and After the Health Transformation Plan	<i>Health Service Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences</i>	2018	Principal Investigator
13	Measuring Equity in the Distribution of Financial Burden of Health Expenditures Using the Fair Share Index from 2008 to 2016	<i>Health Service Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences</i>	2018	Principal Investigator
14	Assessment of the Economic Burden of Air Pollution in Major Cities of Iran in 2017	<i>Department of Environment / Ministry of Health / Shahid Beheshti University of Medical Sciences</i>	2019	Co-Investigator
15	Cost-Effectiveness Analysis of Sarcopenia Screening in Iran	<i>Chronic Diseases Research Center, Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	2019	Principal Investigator
16	Examining Factors Affecting Hospital Costs in Road Traffic Injury (RTI) in 2018	<i>Student Scientific Research Center / Research and Technology Deputy, Tehran University of Medical Sciences</i>	2019	Collaborator
17	Cost-Benefit Analysis of Rehabilitation Services for Multiple Sclerosis (MS) in Iran	<i>Ministry of Health and Medical Education</i>	2020	Co-Investigator
18	Cost-Benefit Analysis of Rehabilitation Services for Spinal Cord Injury (SCI) in Iran	<i>Ministry of Health and Medical Education</i>	2020	Co-Investigator
19	Cost-Benefit Analysis of Rehabilitation Services for Stroke in Iran	<i>Ministry of Health and Medical Education</i>	2020	Main Collaborator
20	Examining the Situation of Multidimensional Poverty and Its Trend in Kerman Province from 2008 to 2018	<i>Welfare Organization of Kerman Province / Kerman University of Medical Sciences</i>	2020	Principal Investigator
21	Assessment of Cryoballoon Ablation Technology Compared to Radiofrequency Ablation in Patients with Atrial Fibrillation	<i>Treatment Deputy, Ministry of Health - Health Technology Assessment Office</i>	2020	Co-Investigator
22	Assessment of Endovascular Aneurysm Repair (EVAR) Technology Compared to Open Repair in Patients with Abdominal Aortic Aneurysm	<i>Treatment Deputy, Ministry of Health - Health Technology Assessment Office</i>	2020	Main Collaborator

23	Economic Burden of Multiple Sclerosis (MS) in Iran from 2011 to 2019	<i>National Institute for Medical Research Development (NIMAD)</i>	2021	Co- Investigator
24	Examining Hospitalization Costs in Burn Patients and Influencing Factors in 2018	<i>Student Research Center, Tehran University of Medical Sciences</i>	2021	Collaborator
25	Health Technology Assessment of Palbociclib in Treating Breast Cancer Patients	<i>Treatment Deputy, Ministry of Health - Health Technology Assessment Office</i>	2021	Co- Investigator
26	Estimating the Economic Burden and Cost-Effectiveness of Sarcopenia Treatment Interventions in Iran	<i>Chronic Diseases Research Center, Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	2022	Principal Investigator
27	Developing Standards and Guidelines for Conducting Health Technology Assessments in Iran	<i>National Institute for Health Research</i>	2022	Principal Investigator
28	Cost-Utility Analysis of Insulin Glargine and Detemir Compared to Isophane Insulin in Type 2 Diabetes Patients in Iran	<i>Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	2023	Principal Investigator
29	Cost-Effectiveness Analysis of Early Insulin Treatment Compared to Oral Medications in Type 2 Diabetes Patients in Iran	<i>Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	2023	Principal Investigator
30	Designing a Prioritization Method for Financing Interventions of the Specific and Severe Diseases Insurance Fund	<i>Health Insurance Research Center</i>	2024	Principal Investigator
31	Economic Evaluation and Prioritization of Interventions for Type 2 Diabetes in Iran	<i>Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	Ongoing	Principal Investigator
32	Estimating the Economic Burden of Type 2 Diabetes in Iran in 2022	<i>Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	Ongoing	Collaborator
33	Measuring Inequality in Various Components of Type 2 Diabetes in Iran	<i>Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	Ongoing	Co- Investigator
34	Measuring Willingness to Pay for Type 2 Diabetes Treatment Interventions in Iran	<i>Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	Ongoing	Co- Investigator
35	Assessing Public Preferences Regarding Various Management Interventions for Type 2 Diabetes in Iran	<i>Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	Ongoing	Co- Investigator
36	Economic Evaluation of MS Medications in First and Second-Line	<i>Health Insurance Research Center</i>	Ongoing	Principal Investigator



Treatments Across Various Disease Groups in Iran

37	Extraction and Evaluation of Existing Policies in SMA Screening and Economic Evaluation of SMA Screening Strategies in Iran	<i>Non-Communicable Disease Management Center - Health Deputy, Ministry of Health / Endocrine and Metabolism Research Institute</i>	Ongoing	Co- Investigator
38	Health Technology Assessment of Portable Analyzer Devices (Point-of-Care Testing) in Emergency Departments of Hospitals in Iran	<i>Treatment Deputy, Ministry of Health - Health Technology Assessment Office / National Institute for Health Research</i>	Ongoing	Principal Investigator
39	Designing a Model for Prioritizing Orphan Medicines in Iran	<i>National Institute for Medical Research Development (NIMAD)</i>	Ongoing	Co- Investigator
40	Examining the Financial Protection Indicators Against Health Expenditures in Households of Type 2 Diabetes Patients in Iran	<i>Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences</i>	Ongoing	Principal Investigator

## Research Articles

1. **Darvishi, A.**, Abdi Dezfouli, R., Ghasemian Z., Akbari-Sari, A., Harirchian MH & Daroudi, R. The Cost-Utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran. *Expert Review of Pharmacoeconomics & Outcomes Research* 02 Aug (2024). <https://doi.org/10.1080/14737167.2024.2388818>
2. Heshmat, R., **Darvishi, A.**, Abdi Dezfouli, R., Nikkhah, A., Radmanesh, R., & Moslemi, E. A short-term economic evaluation of early insulin therapy compared to oral anti-diabetic drugs in order to reduce the major adverse events in type 2 diabetes patients in Iran. *Current Medical Research and Opinion* 02 Apr (2024). <https://doi.org/10.1080/03007995.2024.2333425>
3. **Darvishi A**, Nikkhah A, Mahmudimanesh M, Zargar N, Shafiee G\*, Heshmat R. Socioeconomic inequalities in type 2 diabetes mellitus: a study based on a population-based survey in Iran. *BMC Public Health* 24, 926 (2024). <https://doi.org/10.1186/s12889-024-18452-7>
4. Bashari N, Safaei-Lari M, **Darvishi A**, Daroudi R\*. Cost-Utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran. *Expert Review of Pharmacoeconomics & Outcomes Research* 24 (2), 273-284 (2023). <https://doi.org/10.1080/14737167.2023.2263164>
5. **Darvishi A**, Daroudi R, Fazaeli AA\*. Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model. *Health Economics Review* (2023) Published online: 09 November 2023. <https://doi.org/10.1186/s13561-023-00463-6>
6. Daroudi R, Mousavi MT, Shirazikhah M, Alizadeh Zarei M, Hendi HR, Joghataei F, **Darvishi A\***. Cost-utility analysis of multiple sclerosis rehabilitation in Iran. *Expert Review of Pharmacoeconomics & Outcomes Research* (2023) Published online: 28 Aug 2023. <https://doi.org/10.1080/14737167.2023.2251689>
7. Jasemi, S.V., Zandieh, Z, Zandieh N, Rezaei Hemami M, **Darvishi A**, Abdollahi Z, Heshmat R\*. Is vitamin D supplementation program in Iranian schools effective in reducing adolescent depressive symptoms? Cost effectiveness study. *BMC Public Health* 23, 1393 (2023). <https://doi.org/10.1186/s12889-023-16244-z>
8. **Darvishi A**, AbdiDezfouli R, Fazaeli AA, Daroudi R\*. Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?. *Expert Review of Pharmacoeconomics & Outcomes Research* (2023). <http://dx.doi.org/10.1080/14737167.2023.2263167>.
9. **Darvishi A.**, Shafiee G., Zargar-Balajam N., Rezaei-Hemami M., Ostovar N., Heshmat R\*. Cost-effectiveness analysis of sarcopenia management interventions in Iran. *BMC Public Health* 23, 819 (2023). <https://doi.org/10.1186/s12889-023-15693-w>

10. **Darvishi A**, Mousavi MT, Abdi Dezfouli R, Shirazikhah M, Alizadeh zarei M, Hendi HR, Joghataei F, Daroudi R\*. Cost-benefit analysis of stroke rehabilitation in Iran. *Expert Review of Pharmacoeconomics & Outcomes Research* (2023) 10 Apr 2023.  
<https://doi.org/10.1080/14737167.2023.2200938>
11. **Darvishi, A.**, Daroudi, R., Yaseri, M., Akbari-Sari, A. Public preferences regarding the priority setting criteria of health interventions for budget allocation: results of a survey of Iranian adults. *BMC Public Health* 22, 2038 (2022). <https://doi.org/10.1186/s12889-022-14404-1>
12. Asadollahi M, **Darvishi A**, Azimi A, Annabi M, Jafariazar Z, Heshmat R\*. Economic Burden of Multiple Sclerosis Drugs in Iran during 2011-2019. *Iran J Public Health*. 2023;52(2):407-419.
13. **Darvishi A**; Sadeighipoor P; Darroudi A; Daroudi R. Cost-Utility Analysis of Cryoballoon Ablation versus Radiofrequency Ablation in the Treatment of Paroxysmal Atrial Fibrillation; Case Study: Iran. *PLoS ONE*, 2022; 17(7): e0270642. <https://doi.org/10.1371/journal.pone.0270642>
14. **Darvishi A**; Rezaei Hemami M; Shafiee G\*; Daroudi R; Mohseni M; Hosseini Shekarabi F; Heshmat R. Sarcopenia Screening Strategies in Older People: A Cost Effectiveness Analysis in Iran. *BMC Public Health*. 2021. 21:926.  
i. <https://doi.org/10.1186/s12889-021-10511-7>
15. Yazdi Feyzabadi V, Mehroolhassani MH, **Darvishi A\***. Measuring Catastrophic Health Expenditures and its Inequality: Evidence from Iran's Health Transformation Program. *Journal of Health Policy and Planning*, 2019, 1–10. <https://doi.org/10.1093/heapol/czz031>
16. **Darvishi A**, Goudarzi R\*, Zadeh VH, Barouni. Cost-benefit Analysis of IUI and IVF based on willingness to pay approach; case study: Iran. *PLoS ONE* 2020, 15(7): e0231584.  
i. <https://doi.org/10.1371/journal.pone.0231584>
17. Kosar Hajian, Ramin Abdi Dezfouli, **Ali Darvishi**, Ramin Radmanesh & Ramin Heshmat\*. Tenecteplase in managing acute ischemic stroke: a long-term cost-utility analysis in Iran. *Expert Review of Pharmacoeconomics & Outcomes Research* 2022, 29 Nov 2022.  
i. <https://doi.org/10.1080/14737167.2023.2152008>
18. Mousavi MT; Daroudi R; Shirazikhah M; Alizadeh zarei M; Hendi HR; Joghataei F; **Darvishi A\***. Economic evaluation of spinal cord injury (SCI) rehabilitation in Iran. *Archives of Rehabilitation*. jrehab 2022; 23 (3) :412-433. URL: <http://rehabilitationj.uswr.ac.ir/article-1-2926-en.html>
19. Zandieh N, Rezaei Hemami M, **Darvishi A**, Zarei M, Hasheminejad SM, Abdollahi Z, Heshmat R. The Cost-Effectiveness Analysis of a Nationwide Vitamin D Supplementation Program Among Iranian Adolescents for the Adulthood Cardiovascular Diseases Prevention. *Public Health*. 2021. Volume 198, September: 340-347.  
<https://www.sciencedirect.com/science/article/abs/pii/S0033350621002882>

20. Mina Asadollahi; **Darvishi A**; Azimi AR; Annabi M; Jafariazar Z; Heshmat R\*. Estimation the Medical Cost of Multiple Sclerosis in Iran; 2019-2020. *BMC Health Services Research*. 2022 Feb 2;22(1):137. doi:10.1186/s12913-022-07551-z.
21. Zandieh N, Rezaei Hemami M, **Darvishi A**, Zarei M, Hasheminejad SM, Abdollahi Z, Heshmat R. Economic evaluation of a national vitamin D supplementation program among Iranian adolescents for the prevention of adulthood type 2 diabetes mellitus. *BMC Complementary Medicine and Therapies* 2022, 22(1): 1-9.  
i. <https://doi.org/10.1186/s12906-021-03474-0>
22. **Darvishi A**; Amini-Rarani M; Mehrolhassani MH; Yazdi-Feyzabadi V. Fairness in household financial contribution to the Iran's healthcare system from 2008 to 2018. *BMC Research Note*, 2021. 14:190. <https://doi.org/10.1186/s13104-021-05606-8>
23. Raadabadi M, **Darvishi A\***, Ahmadi B, Soleymani F. Antibiotics Prescription Pattern and their Financial Burden before and after Intervention in Traumatic Injuries. *Trauma Monthly*. 2020, [10.30491/tm.2020.213791.1032](https://doi.org/10.30491/tm.2020.213791.1032)
24. Mehrolhassani MH, Goudarzi R, Yazdi Feyzabadi V, Pourhosseini S, **Darvishi A\***. Efficiency and Productivity Measurement in Research Sector of Iranian Medical Sciences Universities Using Data Envelopment Analysis and Malmquist Index. *Iranian Journal of Epidemiology* 2018; 14, Special Issue (Foundations, Approaches and Performance of Iran's Health System): 273-282. (In Persian) URL: <http://irje.tums.ac.ir/article-1-6139-en.html>
25. Goudarzi R, Mehrolhassani MH, Dehnavieh R, **Darvishi A\***. Performance Assessment of Provincial Units of Social Security Organization in Indirect Health Services Sector using DEA Method; 2012-2014. *Iranian Journal of Epidemiology* 2017; 12(5): 40-54. (In Persian)
26. **Darvishi A**, Goudarzi R\*, Habib Zadeh V, Barouni M. Cost-benefit analysis of pharmaceutical treatments of infertility using willingness to pay approach. *JSSU*. 2018; 26 (3):245-256. (In Persian)
27. Mehrolhassani MH, Goudarzi R, Yazdi Feyzabadi V, Pourhosseini S, **Darvishi A\***. Performance Assessment and Productivity Measurement in Educational Sector of Iranian Medical Sciences Universities Using Data Envelopment Analysis and Malmquist Index. *Iranian Journal of Epidemiology*. 2018; 14, Special Issue (Foundations, Approaches and Performance of Iran's Health System): 273-282. (In Persian)
28. Haghdoost AA, Goudarzi R\*, **Darvishi A**, et al. Modelling the Budget Determination of Educational Sector in Iran's Medical Sciences Universities. *Strides in Development of Medical Education*. 2019 December; 16(1): e81991  
i.
29. **Darvishi A**, Taheri A, Sabermahani A\*. Moral Hazards in Drug Sector and its Financial Burden on Health Insurance Organizations (an Economic Approach to Medical Ethics). *Med Ethics J*. 2018; 12(43): e24. (In Persian)

30. Nojumi M; Rezaei-Hemai M; **Darvishi A**; Mohammadi-Parsa N. Cost-benefit analysis of Down syndrome screening in Iran. *Jundishapur J Health Sci.* 2021;13(2):e113257. doi: [10.5812/jjhs.113257](https://doi.org/10.5812/jjhs.113257)
31. **Darvishi A**, Emamgholipour S, Rajabi M, Mehrolhassani MH, Yazdi Feyzabadi V\*. Investigating Appropriate Threshold for Measuring the Occurrence and Intensity of Households' Exposure to Catastrophic Health Expenditure in Iran. *Iranian Journal of Epidemiology.* 2021; 17 (1) :34-46. (In Persian) URL: <http://irje.tums.ac.ir/article-1-6928-en.html>
32. Mehrolhassani MH, Yazdi Feyzabadi V, **Darvishi A\***. Iranian Households Expenditure Pattern after Iran's Health Transformation Program with Emphasis on Health care Expenditure Trends between 2013 and 2018. *Scientific Journal of Kurdistan University of Medical,* 2021; 26 (3) :117-128. (In Persian) URL: <http://sjku.muk.ac.ir/article-1-5015-en.html>
33. Rezaei-Hemami M; Darvishi A; Mohammadi-Parsa N. Cost-Utility Analysis of Combined First-Trimester Test for Down Syndrome Screening in Iran. *Iranian Journal of Public Health.* 2023. (Accepted Manuscript)

**\*نویسنده مسئول**

## Review of Articles and Research Proposals

### International Journals:

- International journal of equity in health  
Manuscript Peer Reviewer (International Journal)
- BMC International Health and Human Rights  
Manuscript Peer Reviewer (International Journal)
- BMC Public Health  
Manuscript Peer Reviewer (International Journal)
- Communications Medicine  
Manuscript Peer Reviewer (International Journal)
- Frontiers in Global Women's Health  
Manuscript Peer Reviewer (International Journal)
- Medical Journal of The Islamic Republic of Iran (MJIRI)  
Manuscript Peer Reviewer (International Journal)

### Scientific Institutions

- **Reviewer** for national health technology assessment projects at the Treatment Deputy of the Ministry of Health / National Institute for Health Research
- **Reviewer** for health economics research projects (Future Studies Research Institute in Health, Kerman University of Medical Sciences)
- **Reviewer** for health economics research projects (Neyshabur University of Medical Sciences, Neyshabur, Iran)
- **Reviewer** for health economics research projects (Shahid Sadoughi University of Medical Sciences, Yazd, Iran)

## Presented Papers at International Congresses (Oral Presentations and Posters)

1. **Darvishi A**, Heshmat R, Rezaei Hemami M, Shafiee G, Zargar N. Economic Evaluation of Sarcopenia Management Strategies in Iran: A Cost-Effectiveness Analysis. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2024), April 11-14, London-England.
2. **Darvishi A**, Daroudi R, Shafiee G, Heshmat R. Economic Burden of Sarcopenia-Related Disability in the Elderly Population: A Study in Iran. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2024), April 11-14, London-England.
3. **Darvishi A**, Shafiee G, Heshmat R, Radmanesh R, Maleki M. Insulin Glargine and Detemir Compared to Isophane Insulin Among Type 2 Diabetic Patients in Iran: A Cost-Effectiveness Analysis. 10<sup>th</sup> National and the 3rd International Iranian Congress of Epidemiology, 2023, Tehran-Iran.
4. **Darvishi A**, Nikhkhah A, Heshmat R, Shafiee G. Socioeconomic Inequalities in Care of Type 2 Diabetes Mellitus: a Study based on a Population based Survey in Iran. 10<sup>th</sup> National and the 3rd International Iranian Congress of Epidemiology, 2023, Tehran-Iran.
5. R. Heshmat, Rezaei Hemami M, **Darvishi A**, Shafiee G, Daroudi R. Cost-effectiveness Analysis of Sarcopenia Screening Strategies in Iran. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2020)
6. **Darvishi A**, Goudarzi R, Habibzadeh V, Barouni M. Measuring willingness to pay for infertility treatment by IVF in Iran. 2nd international congress on reproductive health and childbearing 2017, Tehran-Iran.
7. **Darvishi A**, Goudarzi R, Barouni M, Habibzadeh V. Cost benefit analysis of infertility treatment by IVF in Iran. 7th Yazd International Congress and Student Award in Reproductive Medicine 2017, Yazd-Iran.

## Past Organizational Responsibilities

- ❖ **Head of the Health Economics Research Group**, Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences, 2023-2024
  
- ❖ **Committed Research Expert**, Chronic Diseases Research Center, Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences, 2023-2024
  
- ❖ **Researcher**, Chronic Diseases Research Center, Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences, from 2020 to 2023
  
- ❖ **Health Economics Researcher**, Health Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, 2016-2017

## Computer Skills and Specialized Software Proficiency

<u>Specialized Software and Tools</u>	<u>Skill Level</u>
<ul style="list-style-type: none"> <li>• <b>Tree Age pro</b> (Economic Evaluation Modelling and Analyses)</li> <li>• <b>Stata software</b> (Econometric and statistical Analyses)</li> <li>• <b>Easy Fit</b> (to fit distributions to data)</li> <li>• <b>Deap</b> (Performance Evaluation)</li> <li>• <b>Frontier</b> (Performance Evaluation)</li> <li>• <b>EMS</b> (Performance Evaluation)</li> <li>• <b>Super Decisions</b> (MCDA)</li>   <li>○ <b>Artificial intelligence tools in education and research</b></li> </ul>	<i><u>Advanced</u></i>
<ul style="list-style-type: none"> <li>• <b>Eviews</b> (Econometric Analyses)</li> <li>• <b>SPSS software</b> (Statistical Analyses)</li> <li>• <b>SPSS Modeler</b> (Data mining)</li> <li>• <b>AirQ+</b> (Quantifying the health burden and impact of air pollution)</li> <li>• <b>Comfar</b> (Economic Evaluation)</li> <li>• <b>PARSIAN accounting software</b> (Accounting)</li> </ul>	<i><u>Intermediate</u></i>



## Research Interests

- ❖ Health Technology Assessment (HTA)
- ❖ Economic evaluation of health interventions
- ❖ Resource allocation and prioritization of health interventions and technologies
- ❖ Estimation of equity, financial protection, and inequality in health
- ❖ Estimation of efficiency and productivity in the health system
- ❖ Multi-Criteria Decision Analysis (MCDA)
- ❖ Evaluation and feasibility studies of health projects

## Language Proficiency

- **Persian** (*native*)
- **English** (*working proficiency*)